NEWS AND MEDIAS
- BY :
- United States
Virtual clinics for epilepsy care?
Bridging the healthcare gap: Building the case for epilepsy virtual clinics in the current healthcare environment
In this article published in “Epilepsy & Behavior” journal, authors question themselves about access to healthcare: how can we facilitate access to quality care in a healthcare environment transformed by the pandemic? Difficulties in care continuity have emerged for patients suffering from serious chronic disorders, who usually require regular visits to their specialist.
To support a healthcare system greatly impacted by the pandemic, authors investigate virtual clinics and telehealth services to optimize care for these patients.
The article takes the situation of epileptic patients, who do not have enough specialist available close to their home. An absence that can be explained by the disease’s diagnostic test of reference, the electroencephalogram (EEG). A test that remains poorly recognized outside epilepsy. During this period, the lack of availability of specialists has also emerged as an issue.
These barriers to continued quality care can be overcomed by the introduction of virtual clinics. Clinics that would place the technologies directly in patients’ homes or at local clinics near the patients’ homes. This way, patients could benefit from specialists that provide quality care, anywhere in the world, at any time of the day.
- Press release
Report of EEG Finding on Critically ill Patients with COVID‐19
Paris & Atlanta, June 15th 2020 – BioSerenity publishes in the Annals of Neurology its discovery on critically ill patients with COVID-19. The discovery made while interpretation EEG for COVID-19 patients warns healthcare professionals about the need of performing an EEG in COVID-19 patients presenting neurological disorders.
BioSerenity, partner of the APHP (French Parisian hospital) for the performing and interpretation of EEG exam with its service Neurophy, has been contacted several time in the begining of the surge of the COVID-19 pandemic to perform EEG on ICU patients.
The EEGs prescribed on patients showing altered mental status, delayed awakening, or poor arousal, has allowed to highlight central nervous system disorders linked to COVID-19
The characteristic EEG anomalies observed by Neurophy’s interpreting doctors has allowed to match them to the neuro invasiveness of COVID-19.
The neurological impact of COVID-19: Interview of Pr. Vespignani
19th of April, professor Hervé Vespignani, BioSerenity’s French medical director was interviewed on French live television and radio to talk about neurological consequences observed in COVID-19 patients. In the interview, the professor speaks about the recent discovery made by Neurophy’s team of EEG irregularities in some COVID-19 patients.
These abnormalities, which are characteristics of an encephalitis, show the virus’ impact the cerebral cortex through an inflammatory mechanism. The professor on the behalf of his team, warns the medical population, through these interviews and a coming publication, to stay alert for potential neurological manifestations in COVID-19 patients. He even recommends the systematization of EEG exploration for patients in reanimation that experienced a delay in waking-up from the induced coma, for the more severe patients that required respiratory support.
Indeed, this delay, if not explained by complications linked to the sedation could be explained by the inflammation. Hence the importance of performing an EEG as soon as possible to avoid any neurological consequences due to the delay in diagnosing the encephalitis.
BNP Paris and CA Champagne Bourgogne sign a syndicate loan with Bioserenity.
"Made in France" exhibition, BioSerenity at the Elysée Palace
Paris, January 18th, 2020 – BioSerenity exhibited a prototype of a connected textile, suitable for a pediatric use, at the “Made in France” exhibition, held at the Elysée Palace in Paris this weekend.
BioSerenity’s medical devices are developed and manufactured in France, in Rosières-prés-Troyes factory, capitalizing on a territorial know-how in textile. At the crossroads of digital and medical innovation, BioSerenity offers connected medical devices, providing continuous and long-term recording at the patient’s home or at the hospital, to help healthcare professionals to diagnose and support their patients.
BioSerenity attended the French Congress of Psychiatry
Nice, december 4th 2019 – BioSerenity and its medical subsidiary company attended the French Congress of Psychiatry in Nice, between the 4th and 7th december 2019.
During this event, the interest of alectrophysiology in psychiatry was highlighted during a workshop moderated by Prof. Schwan (Nancy) in presense of Dr. Micoulaud-Franchi (Bordeaux), Pr. Vespignani (Nancy ) and Dr. Schwitzer (Nancy). In particular, during this conference, the importance of electrophysiological monitoring (EEG, PSG and ERG) in psychiatry was emphasized.
More particularly, according to the speakers, the evaluation of the EEG as part of the patient journey in psychiatry should be used as a bioelectric marker of pathologies treatable by non-psychiatric therapeutics, but also as a bioelectric marker of the response and tolerance to treatments, particularly in narrow margin specialized therapies. In addition, EEG could be used as a bioelectric marker in a psychophysiological perspective to consider personalized neuro-modulatory therapies.
Also, psychiatric comorbidities and sleep have been highlighted as well as the importance of investigating the patients’ sleep quality in a systematic way in the care pathways in psychiatry.
Finally, the ERG was recognized by stakeholders as a tool for evaluation and prediction of the response to psychiatric treatment and its use could be relevent in clinical practice for the differential diagnosis between unipolar depression and bipolar depression.
Paris, November 22nd – The 12th of December 2019 will be held the Day of Action on Atrial Fibrillation. The Atrial Fibrillation is characterized by an irregular heart rate among other characteristics.
BioSerenity supports this testing and awareness day organized by Action Coeur. Coordinated by the professor Gilles Montalescot, cardiologist within the Cardiolgy Institute of La Pitié Salpêtrière hospital, Action Cœur is an independent academic not for profit Academic Research Organization, acting and promoting clinical research and prevention in the field of cardiovascular diseases.
Join Action Coeur on the 12th of December from 9:00 am to 5:00 pm at the Cardiolgy Institute of La Pitié Salpêtrière hospital to be informed on atrial fibrillation.
Venez vous informer à l’Institut de Cardiologie à l’Hôpital de la Pitié Salpêtrière le 12 décembre 2019 entre 9h et 17h.
Symposium: Health data and collective intelligence
Paris, November 18th – Over the last few years, the AI has invited itself within our everyday lives to improve them. Continuing this trend, the result will may be the change of the health system as we know it today.
In this environment, the BioSerenity team attended to the “Health Data and Collective Intelligence” conference during which the future use of the health data was introduced by the State representatives and health players.
- Press release
A new branch of BioSerenity in Nancy University Hospital
Nancy, November 20th, the Nancy-Barbois Regional University Hospital Center opens an economic research project center focused on healthcare, within the Health Research and Innovation Institute.
In this space dedicated to hosting startups, companies under a research agreement with the Regional University Hospital Center, and reaseachers developing innovations, BioSerenity is proud to be part of the first startups opening a new branch in the Technopôle Henri-Poincaré.
For more information please consult our press release.
- Press release
BioSerenity acquires SleepMed
Paris, September 22nd, 2019 – Following its recent integration among the Next40 index, BioSerenity announces the acquisition of SleepMed Inc. a US based provider of Sleep and Neuroscience Diagnostics.
SleepMed operates over 70 Sleep Labs in the continental United States. Through its services, SleepMed has helped diagnose hundreds of thousands of patients suffering from sleep and seizure disorders.
Another significant step which consolidate BioSerenity presence in the USA to become one of the leaders of Sleep Medicine and Neuroscience in the United States.